| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
BioMarin Pharmaceutical Inc (NASDAQ: BMRN)
BMRN Technical Analysis
4
| As on 9th Jun 2023 BMRN SHARE Price closed @ 91.37 and we RECOMMEND Buy for LONG-TERM with Stoploss of 84.96 & Strong Buy for SHORT-TERM with Stoploss of 85.90 we also expect STOCK to react on Following IMPORTANT LEVELS. |
BMRNSHARE Price
| Open | 92.13 | Change | Price | % |
| High | 92.23 | 1 Day | -0.89 | -0.96 |
| Low | 91.18 | 1 Week | 4.43 | 5.10 |
| Close | 91.37 | 1 Month | -1.08 | -1.17 |
| Volume | 621352 | 1 Year | 1.72 | 1.92 |
| 52 Week High 117.27 | 52 Week Low 71.48 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| BMRN Daily Charts |
BMRN Intraday Charts |
Whats New @ Bazaartrend |
BMRN Free Analysis |
|
|
BMRN Important Levels Intraday
| RESISTANCE | 93.39 |
| RESISTANCE | 92.74 |
| RESISTANCE | 92.34 |
| RESISTANCE | 91.94 |
| SUPPORT | 90.80 |
| SUPPORT | 90.40 |
| SUPPORT | 90.00 |
| SUPPORT | 89.35 |
BMRN Forecast April 2024
| 4th UP Forecast | 116.59 |
| 3rd UP Forecast | 108.5 |
| 2nd UP Forecast | 103.5 |
| 1st UP Forecast | 98.5 |
| 1st DOWN Forecast | 84.24 |
| 2nd DOWN Forecast | 79.24 |
| 3rd DOWN Forecast | 74.24 |
| 4th DOWN Forecast | 66.15 |
BMRN Weekly Forecast
| 4th UP Forecast | 102.26 |
| 3rd UP Forecast | 98.77 |
| 2nd UP Forecast | 96.61 |
| 1st UP Forecast | 94.45 |
| 1st DOWN Forecast | 88.29 |
| 2nd DOWN Forecast | 86.13 |
| 3rd DOWN Forecast | 83.97 |
| 4th DOWN Forecast | 80.48 |
BMRN Forecast2024
| 4th UP Forecast | 182.02 |
| 3rd UP Forecast | 152.95 |
| 2nd UP Forecast | 134.98 |
| 1st UP Forecast | 117.01 |
| 1st DOWN Forecast | 65.73 |
| 2nd DOWN Forecast | 47.76 |
| 3rd DOWN Forecast | 29.79 |
| 4th DOWN Forecast | 0.72 |
BioMarin Pharmaceutical Inc ( NASDAQ USA Symbol : BMRN )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
BMRN Business Profile
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; BMN 307, an AAV5 mediated gene therapy, which is in phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; BMN 331 for the treatment of hereditary angioedema; BMN 255 for the treatment of chronic renal disease; and BMN 351 for the treatment of Duchenne Muscular Dystrophy. The company has collaboration and license agreements with Sarepta Therapeutics, Asubio Pharma Co., Ltd., and DiNAQOR AG. The company serves specialty pharmacies, hospitals, and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration with Allen Institute. BioMarin Pharmaceutical Inc. was incorporated in 1996 and is headquartered in San Rafael, California. Address: 770 Lindaro Street, San Rafael, CA, United States, 94901
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service